Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Autologous TGF beta resistant HER2 EBV CTLs |
| Synonyms | |
| Therapy Description |
Autologous TGF beta resistant HER2 EBV CTLs are EBV-specific autologous cytotoxic T lymphocytes that express a chimeric ERBB2 (HER2) antigen receptor as well as a dominant negative TGF-beta receptor, which target ERBB2 (HER2) expressing tumor cells, potentially resulting in increased CTL-mediated tumor cell death (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Autologous TGF beta resistant HER2 EBV CTLs | HER2 (ERBB2) Immune Cell Therapy 9 | Autologous TGF beta resistant HER2 EBV CTLs are EBV-specific autologous cytotoxic T lymphocytes that express a chimeric ERBB2 (HER2) antigen receptor as well as a dominant negative TGF-beta receptor, which target ERBB2 (HER2) expressing tumor cells, potentially resulting in increased CTL-mediated tumor cell death (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00889954 | Phase I | Autologous TGF beta resistant HER2 EBV CTLs | Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy | Completed | USA | 0 |